AIM - AIM ImmunoTech Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.6600
+0.6200 (+30.39%)
At close: 4:00PM EDT

3.0500 +0.39 (14.66%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close2.0400
Open2.2700
Bid3.0400 x 1200
Ask2.7500 x 1000
Day's Range2.2400 - 3.4500
52 Week Range0.3810 - 14.8106
Volume28,338,784
Avg. Volume7,797,559
Market Cap68.004M
Beta (5Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)-5.8730
Earnings DateOct 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
  • ACCESSWIRE

    AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

    OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development.

  • ACCESSWIRE

    AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19

    OCALA, FL / ACCESSWIRE / March 9, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the National Institute of Infectious Diseases (NIID) in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The experimental program will be conducted at both the NIID and the University of Tokyo.

  • Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April
    MarketWatch

    Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April

    Shares of Inovio Pharmaceuticals Inc. rallied more than 16% Tuesday, after the company said it’s accelerating the timeline for development of a vaccine to treat the coronavirus COVID-19 and expects to start human trials in the U.S. next month.

  • ACCESSWIRE

    AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic

    OCALA, FL / ACCESSWIRE / February 27, 2020 / AIM ImmunoTech (NYSE American: AIM, or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the Company has joined with ChinaGoAbroad (CGA) to facilitate the entry of AIM's experimental drug Ampligen into the People's Republic of China (PRC) for use as a prophylactic/early-onset therapeutic against COVID-19, the new SARS-like coronavirus infection that has reached epidemic proportions. CGA is a member-based online information platform and offline advisory firm serving to facilitate two-way international transactions relating to the PRC in close collaboration with the China Overseas Development Association (CODA), which had up until recently reported to the PRC National Development and Reform Commission (NDRC), which in turn reports to the State Council (China's cabinet).

  • ACCESSWIRE

    AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

    OCALA, FL / ACCESSWIRE / February 18, 2020 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided its stockholders with an update on its efforts to develop Ampligen as a protective therapeutic and a vaccine in the new coronavirus epidemic. Ampligen, the company's flagship drug, has a commercial approval in Argentina, early-access therapeutic approval in the Netherlands, and is in numerous FDA-authorized clinical trials in the United States. This letter provides a detailed scientific basis for why the company is moving forward in the important and volatile Wuhan coronavirus space.

  • ACCESSWIRE

    AIM ImmunoTech’s CEO to Appear Live Today on FOX Business Network’s The Claman Countdown and Cheddar’s Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus

    OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive Officer, Thomas K. Equels, will appear live today as a guest on FOX Business Network's The Claman Coutdown and Cheddar's Opening Bell. Mr. Equels is scheduled to appear on Cheddar's Opening Bell with hosts Hope King and Nora Ali at 10:20 AM ET.

  • GlobeNewswire

    AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

    AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company’s efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States’ National Institutes of Health contracted studies to evaluate potential treatments for SARS.

  • ACCESSWIRE

    AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

    OCALA, FL / ACCESSWIRE / February 11, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company's efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States' National Institutes of Health contracted studies to evaluate potential treatments for SARS.

  • ACCESSWIRE

    AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies

    OCALA, FL / ACCESSWIRE / February 5, 2020 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced posting by the University of Pittsburgh Medical Center (UPMC) on January 28, 2020 via ClinicalTrials.gov of completion of an independent, third-party clinical trial to evaluate the safety and activity of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and Ampligen (rintatolimod), given with a dendritic cell (DC) vaccine, as a potential treatment for metastatic peritoneal surface malignancies after standard of care surgery. The principal investigator of the trial was David L. Bartlett, MD, an internationally recognized cancer researcher at UPMC, in collaboration with the National Cancer Institute.

  • Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares
    Simply Wall St.

    Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • ACCESSWIRE

    AIM ImmunoTech to Present at the Investor Summit in Philadelphia

    OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...

  • ACCESSWIRE

    AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

    OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - today provided its stockholders with an update on the first three quarters of 2019 and detailed expected upcoming milestones in clinical studies using its drug Ampligen. This has been a transformational year for AIM ImmunoTech. Several more clinical trials are slated for 2020.

  • ACCESSWIRE

    CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not December 31, 2019. OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - provides a business update for the third quarter ended September 30, 2019, and has filed its form 10-Q with the U.S. Securities and Exchange Commission, which is available on the Company's website. Announced the U.S. Department of Defense's (DOD) $6.42M "Breakthrough Award" to Roswell Park Comprehensive Cancer Center to fund a clinical trial to study Ampligen as a potential synergistic agent in combination with several other immunotherapies, such as pembrolizumab, in the treatment of brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    OCALA, FL / ACCESSWIRE / October 23, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, ...

  • ACCESSWIRE

    AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA, ...

  • ACCESSWIRE

    AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE American:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced the pricing of an underwritten public offering of (i) 1,740,550 shares of common stock together with common stock warrants (the "common warrants") to purchase 1,740,550 shares of common stock and (ii) 7,148,310 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 7,148,310 shares of common stock. The shares of common stock (or pre-funded warrants, as applicable) and accompanying common warrants are being sold together at a combined public offering price of $0.90 per share.

  • ACCESSWIRE

    AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announces the U.S. Department of Defense (DoD) has granted $8.32 million in funding in another "Breakthrough Award". This award is to Moffitt Cancer Center for a Phase 2 clinical study of a combination of therapies, including the Company's drug Ampligen, in patients with brain-metastatic breast cancer (BMBC).

  • ACCESSWIRE

    AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as severe chronic fatigue syndrome (CFS) - has received clearance to export to Argentina from the U.S. Food and Drug Administration (FDA) its flagship drug Ampligen. In 2016, the company announced the approval of its New Drug Application (NDA) from Argentina's Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for the commercial sale of Ampligen for the treatment of CFS. The FDA requires certain regulations be met in order to export a drug manufactured in the United States to a foreign country.

  • Benzinga

    AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award'

    Shares of thinly-traded microcap AIM ImmunoTech Inc. (NYSE: AIM ) are trading sharply higher after the company announced the Department of Defense granted a four-year, $6.42 million "Breakthrough ...

  • ACCESSWIRE

    AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - today announced that the U.S. Department of Defense (DOD) has granted a four-year, $6.42 million "Breakthrough Award" to Roswell Park Comprehensive Cancer Center (Roswell Park) for a clinical study of a combination of therapies, including the company's drug Ampligen, in patients with brain-metastatic breast cancer (BMBC). Drs. Shipra Gandhi and Pawel Kalinski of Roswell Park Comprehensive Cancer Center will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for brain-metastatic breast cancer.

  • ACCESSWIRE

    AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - today named Ellen Lintal as its new Chief Financial Officer. The Board of Directors unanimously approved Lintal for the senior leadership position. Lintal joined the company - then named Hemispherx Biopharma Inc. - in 2018 as Vice President of Finance & Control, before being promoted to Chief Accounting Officer earlier this year.

  • ACCESSWIRE

    AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers ...

  • ACCESSWIRE

    AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers ...